Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Tweet Send to a FriendGet Alerts REGN Hot Sheet
Price: $231.38 -4.69%
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade REGN Now!
Citi maintains a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $68.
Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.
Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $96.86 yesterday, with a 52 week range of $33.90-$97.56.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.
Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $96.86 yesterday, with a 52 week range of $33.90-$97.56.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Madison Square Garden (MSG) is a Stock to Own on Sport Team Value and Hidden Value of The Garden - Needham & Company
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Citi
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
